Home
Clint Login
Become A Client: Register Now
(Clinic (or) Hospital (or) Doctor (or) Collection Center)
S.No | Test_Code | Test Type | Method | Description | Sample | Schedule | TAT |
---|---|---|---|---|---|---|---|
S.No | Test_Code | Test Type | Method | Description | Sample | Schedule | TAT |
1 | BGSNG71 | SANGERS SEQUENCING | SANGERS | PATERNITY TESTING - 2 PARENTS & 1 CHILD STR ANALYSIS by IDENTIFILER | WB in EDTA | DAILY | 7 DAYS |
2 | BGSNG70 | SANGERS SEQUENCING | SANGERS | PATERNITY TESTNG - 1 PARENT & CHILD | WB in EDTA | DAILY | 7 DAYS |
3 | BGSNG68 | SANGERS SEQUENCING | Sangers | Hepatitis C Virus (HCV) – Genotyping | WB in EDTA | DAILY | 3 DAYS |
4 | BGSNG67 | SANGERS SEQUENCING | Sangers | Hepatitis B Virus (HBV) Drug Resistance Assay | WB in EDTA | DAILY | 3 DAYS |
5 | BGSNG66 | SANGERS SEQUENCING | Sangers | Hepatitis B Virus (HBV) – Genotyping | WB in EDTA | DAILY | 3 DAYS |
6 | BGSNG65 | SANGERS SEQUENCING | Sangers | AML - NPM1 ( Nucleophosmin -1) gene mutation Assay | WB in EDTA | DAILY | 7 DAYS |
7 | BGSNG64 | SANGERS SEQUENCING | Sangers | AML - FLT3 (fms like tyrosine kinase 3) Gene Mutation Assay | WB in EDTA | DAILY | 7 DAYS |
8 | BGSNG63 | SANGERS SEQUENCING | Sangers | AML - CEBPA (CCAAT/Enhancer Binding Protein) mutations | WB in EDTA | DAILY | 7 DAYS |
9 | BGSNG62 | SANGERS SEQUENCING | Sangers | AML PCR PANEL II - FLT3, NPM1 & C/EBPA ( With Normal Cytogenetics) | WB in EDTA | DAILY | 7 DAYS |
10 | BGSNG61 | SANGERS SEQUENCING | Sangers | KRAS, NRAS, BRAF MUTATION ANALYSIS | WB in EDTA | DAILY | 7 DAYS |
11 | BGSNG60 | SANGERS SEQUENCING | Sangers | Thiopurine Methyltransferase (TPMT - *2, *3A, *3B, *3C) Genotyping | Peripheral blood | DAILY | 5-7 days |
12 | BGSNG59 | SANGERS SEQUENCING | Targeted mutation Analysis (more than 2 mutations) | Peripheral blood/Amniotic fluid / Cord Blood/Chorionic villi | - | 10-15 days | |
13 | BGSNG58 | SANGERS SEQUENCING | Targeted mutation Analysis (2 mutations) | Peripheral blood/Amniotic fluid / Cord Blood/Chorionic villi | - | 10-15 days | |
14 | BGSNG57 | SANGERS SEQUENCING | Targeted mutation Analysis (1 mutation) | Peripheral blood/Amniotic fluid / Cord Blood/Chorionic villi | - | 10-15 days | |
15 | BGSNG56 | SANGERS SEQUENCING | Solid tumor Combo1 [EGFR,ALK1,ROS1,MET,PD L1] | Tumor tissue | - | 5-7 days | |
16 | BGSNG55 | SANGERS SEQUENCING | QF PCR Panel [13,18,21,XY] + MCC | Amniotic fluid / Chorionic villi/ Cord Blood | - | 1-2 days | |
17 | BGSNG54 | SANGERS SEQUENCING | Pre-implantation Genetic Disorder/PGD HLA Typing (Single Embryo) | Trophectoderm | - | 15-20 days | |
18 | BGSNG53 | SANGERS SEQUENCING | Pre-implantation Genetic Disorder/PGD (Single Embryo) with maternal DNA contamination check | Trophectoderm + EDTA blood of mother for MCC | - | 15-20 days | |
19 | BGSNG52 | SANGERS SEQUENCING | Pre-implantation Genetic Disorder/PGD (Single Embryo- 1 mutation) | Trophectoderm | - | 15-20 days | |
20 | BGSNG51 | SANGERS SEQUENCING | Pre-implantation Genetic Disorder/PGD (Single gene Disorder- Known mutation)- Baseline | Peripheral blood of parents and affected child | - | 15-20 days | |
21 | BGSNG50 | SANGERS SEQUENCING | SANGERS SEQUENCING | POLE gene Mutation Analysis | FFPE | - | 7-8 days |
22 | BGSNG49 | SANGERS SEQUENCING | PIK3CA Mutation Analysis (Exon 7, 9 & 20) | Tumor tissue | - | 7-8 days | |
23 | BGSNG48 | SANGERS SEQUENCING | NRAS Mutation Analysis (codons 12 & 13) | Tumor tissue | - | 7-8 days | |
24 | BGSNG47 | SANGERS SEQUENCING | NPM1 Mutation Analysis (Exon 12 insertion) | Bone Marrow/Peripheral Blood | - | 7-8 days | |
25 | BGSNG46 | SANGERS SEQUENCING | SANGERS | NUDT15 gene Mutation analysis | Peripheral Blood | DAILY | 7-8 days |
26 | BGSNG45 | SANGERS SEQUENCING | Myeloproliferative Leukemia Mutation Screening (MPL - S505N; W515L) | Bone marrow / Peripheral blood | - | 7-8 days | |
27 | BGSNG44 | SANGERS SEQUENCING | MYD88 gene Mutation | Peripheral blood/Tumor tissue | - | 5-7 days | |
28 | BGSNG43 | SANGERS SEQUENCING | Microsatellite Instability (MSI) (Lynch Syndrome/Colorectal Cancer) | Peripheral blood | - | 7-8 days | |
29 | BGSNG42 | SANGERS SEQUENCING | MECP2 Full Gene Mutation Analysis (RETT Syndrome) | Peripheral blood | - | 8-10 days | |
30 | BGSNG41 | SANGERS SEQUENCING | KRAS Mutation Screening (Codons 12 & 13) | Tumor tissue | - | 7-8 days | |
31 | BGSNG40 | SANGERS SEQUENCING | Jak 2 Mutation Detection Panel (Exons 12) | Bone Marrow/Peripheral Blood | - | 7-8 days | |
32 | BGSNG39 | SANGERS SEQUENCING | Jak2 Mutation Detection Panel (Exons 12-15) | Bone marrow / Peripheral blood | - | 7-8 days | |
33 | BGSNG38 | SANGERS SEQUENCING | Irnotecan Toxicity Assessment | Peripheral Blood | - | 7-8 days | |
34 | BGSNG37 | SANGERS SEQUENCING | IGHV Mutation load | Bone marrow / Peripheral blood | - | 7-8 days | |
35 | BGSNG36 | SANGERS SEQUENCING | IDH1 & IDH2 Mutation Analysis | Tumor tissue | - | 7-8 days | |
36 | BGSNG35 | SANGERS SEQUENCING | Human Papilloma Virus - HPV16, 18 & HIGH RISK GENEOTYPES | Cervical swab | - | 7-8 days | |
37 | BGSNG34 | SANGERS SEQUENCING | Human Inmmuno-defecincy Virus - 1 (HIV-1) Drug Resistance Genotype | Peripheral blood/Plasma/Serum | - | 20-21 days | |
38 | BGSNG33 | SANGERS SEQUENCING | HLA-B*57:01 Genotyping (for Abacavir Hypersensitivity) | Peripheral blood | - | 7-8 days | |
39 | BGSNG32 | SANGERS SEQUENCING | HLA-DRB1*1501 Genotyping (Multiple Sclerosis) | Peripheral blood | - | 7-8 days | |
40 | BGSNG31 | SANGERS SEQUENCING | HLA-B*1502 Genotyping (Carbamazepine) | Peripheral blood | - | 7-10 days | |
41 | BGSNG30 | SANGERS SEQUENCING | Hepatitis C Virus (HCV) Genotype | Peripheral blood/Plasma | - | 20-21 days | |
42 | BGSNG29 | SANGERS SEQUENCING | Hepatitis B Virus (HBV) Genotype | Peripheral blood/Plasma | - | 7-8 days | |
43 | BGSNG28 | SANGERS SEQUENCING | Hemochromatosis HFE Full | Peripheral blood | - | 4-6 weeks | |
44 | BGSNG27 | SANGERS SEQUENCING | Hemochromatosis Common Mutation Analysis in HFE Gene (H63D, S61C & C282Y) | Peripheral blood | - | 7-10 days | |
45 | BGSNG26 | SANGERS SEQUENCING | GATA2 Full length gene sequencing (Chronic Neutropenia, MonoMac Syndrome, Mylodysplasia, AML) | Bone Marrow/Peripheral Blood | - | 15 days | |
46 | BGSNG25 | SANGERS SEQUENCING | GATA1 Full length gene sequencing | Bone Marrow/Peripheral Blood | - | 15 days | |
47 | BGSNG24 | SANGERS SEQUENCING | 5-Flurouracil (5-FU) Toxicity and Chemotherapeutic Response (DPYD variants) | Peripheral blood | - | 3-4 days | |
48 | BGSNG23 | SANGERS SEQUENCING | Erythropoetin receptor gene Mutation Analysis | Peripheral blood | - | 7-8 days | |
49 | BGSNG22 | SANGERS SEQUENCING | Fragile X (FMR1) Carrier Screening | Peripheral blood | - | 8-10 days | |
50 | BGSNG21 | SANGERS SEQUENCING | Epidermal Growth Factor Receptor Mutation Analysis (EGFR - Exon 18, 19, 20, 21) | Tumor tissue | - | 3-4 days | |
51 | BGSNG20 | SANGERS SEQUENCING | DMD carrier screening (79 Exons) | Peripheral blood | - | 7-10 days | |
52 | BGSNG19 | SANGERS SEQUENCING | CXCR4 gene Mutation | Peripheral Blood | - | 7-8 days | |
53 | BGSNG18 | SANGERS SEQUENCING | Cytochrome P450 2C19 Genotyping (CYP2C19) Clopidogrel resistance (*2,*3,*4,*10) | Peripheral blood | - | 7-8 days | |
54 | BGSNG17 | SANGERS SEQUENCING | Cytochrome P450 2D6 Genotyping (CYP2D6 - Alleles) | Peripheral blood | - | 7-8 days | |
55 | BGSNG16 | SANGERS SEQUENCING | Cystic Fibrosis mutation screening (CFTR - Del 508 ) | Peripheral blood | - | 7-8 days | |
56 | BGSNG15 | SANGERS SEQUENCING | Cystic Fibrosis mutation screening (CFTR - Del 508)[Prenatal ] | Amniotic fluid / Chorionic villi / Cord blood +EDTA blood of mother | - | 7-8 days | |
57 | BGSNG14 | SANGERS SEQUENCING | Criggler Najjar Syndrome | Peripheral Blood | - | 7-8 days | |
58 | BGSNG13 | SANGERS SEQUENCING | Colorectal Cancer Panel [NRAS,KRAS,BRAF] | Tumor tissue | - | 7-8 days | |
59 | BGSNG12 | SANGERS SEQUENCING | Chronic Neutrophilic Leukemia (CNL)(CSF3R gene exon 14 & 17; SETBP gene - exon 4) | Bone Marrow/Peripheral Blood | - | 7-8 days | |
60 | BGSNG11 | SANGERS SEQUENCING | cKIT Mutation Screening (Exons 9, 11, 13, 17) AML | Peripheral blood | - | 7-8 days | |
61 | BGSNG10 | SANGERS SEQUENCING | CEBPA Full Gene Mutation | Peripheral Blood | - | 5-6 days | |
62 | BGSNG09 | SANGERS SEQUENCING | CALR Mutation Analysis (Deletion or Insertion in Exon 9) | Bone Marrow/Peripheral Blood | - | 7-8 days | |
63 | BGSNG08 | SANGERS SEQUENCING | BRAF Mutation Analysis (V600E) | Tumor tissue | - | 7-8 days | |
64 | BGSNG07 | SANGERS SEQUENCING | Beta Thalassemia-HBB Full Gene Analysis (Couple + Prenatal) [TRIO ANALYSIS] | Amniotic fluid / Chorionic villi / Cord blood + WB -EDTA of parents | - | 8-10 days | |
65 | BGSNG06 | SANGERS SEQUENCING | Beta Thalassemia-HBB Full gne - Couple | Peripheral blood | - | 8-10 days | |
66 | BGSNG05 | SANGERS SEQUENCING | Beta Thalassemia-HBB Full gne - Single | Peripheral blood | - | 8-10 days | |
67 | BGSNG04 | SANGERS SEQUENCING | BCR-ABL1 Kinase Domain Mutations (IRMA) | Bone marrow / Peripheral blood | - | 20-21 days | |
68 | BGSNG03 | SANGERS SEQUENCING | AML Extended Panel (BCR/ABL,AML/ETO, CBFB, PML/RARA, FLT3, NPM1, CEBPA) | Bone marrow / Peripheral blood | - | 7-8 days | |
69 | BGSNG02 | SANGERS SEQUENCING | Achondroplasia (FGFR3 full gene sequence analysis) | Peripheral blood/Amniotic Fluid/ Chorionic villi/ Cord blood | - | 2-3 weeks | |
70 | BGSNG01 | SANGERS SEQUENCING | Sangers | Achondroplasia Mutation Analysis (FGFR3 gene G1138A, G1138C) | Peipheral blood | DAILY | 10-12 days |
71 | BGSNG69 | SANGERS SEQUENCING | Sangers | C KIT MUTATIONS - EXONS 9,11, 13, 17 | WB EDTA | DAILY | 5 DAYS |